(Brigham and Women's Hospital) New research led by the TIMI Study Group at Brigham and Women's Hospital in collaboration with Brown University and the University of Geneva reassuringly finds no association between the use of the PCSK9 inhibitor evolocumab and a decline in memory or cognitive function.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2mDdwc7
No comments:
Post a Comment